Eucare Pharmaceuticals P Ltd - Due diligence report

A 360° intelligence report on Eucare Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress…

1996-03-18 44., Tamil Nadu Active Unlisted Active Compliant
Share
Connect MCP
EP Eucare Pharmaceuticals P Ltd
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Eucare Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
70/100
Trust Score
Moderate

Eucare Pharmaceuticals is assessed as Moderate with a Trust Score of 70/100. Eucare Pharmaceuticals is an active private limited indian non-government company incorporated in 1996, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 12 Aug 2026 from the latest processed filings. Eucare Pharmaceuticals P Ltd snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
25/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.

Charges position: 1 open (60.00 Lakh) · 3 satisfied (5.79 cr).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India3 48.0 cr
The Hongkong And Shanghai Banking Corporation Limited1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
PRATIK SANTOSH BHIDE 01234567 Director 01/04/2018 6 yrs Approved
GUIREC LE LOUS 01234567 Director 01/04/2018 6 yrs Approved
GAVIN JOHN ASHTON 01234567 Director 01/04/2018 6 yrs Approved
RONAN JEAN LOUIS BLANCHARD 01234567 Director 01/04/2018 6 yrs Approved
Javier Camps Hernan Perez 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Hcp Healthcare Asia Pte. Ltd.
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 6 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Hcp Healthcare Asia Pte. Ltd. Holding Company 74.00%

Key managerial personnel: PRATIK SANTOSH BHIDE (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 60
Growth signals & trust indicators
Operating for 30+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
Negative net worth.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence74/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment48/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 60.00 Lakh already registered.
  • Compliance record supports lending.
Investor view42/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
20 Jan 2025
Director appointed
Javier Camps Hernan Perez (Director)
11 Oct 2024
Director ceased
RONAN JEAN LOUIS BLANCHARD
11 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
17 Nov 2023
Charge satisfied
State Bank Of India
05 Oct 2023
Charge satisfied
State Bank Of India
04 Oct 2023
Charge satisfied
State Bank Of India
22 Jun 2022
Director ceased
PRATIK SANTOSH BHIDE
09 Jun 2022
Director appointed
PRATIK SANTOSH BHIDE (Managing Director)
31 Mar 2022
Share transfer (FY 2022)
76479.00000000 shares to HCP Healthcare Asia PTE Limited HCP Healthcare Asia PTE Limited
Share transfer (FY 2022)
38240.00000000 shares to HCP Healthcare Asia PTE Limited HCP Healthcare Asia PTE Limited
Share transfer (FY 2022)
1.00000000 shares to Laboratoires Urgo Laboratoires Urgo
30 Nov 2021
Director ceased
BIJAL ARVIND SHAH
31 Mar 2021
Share transfer (FY 2021)
87914.00000000 shares to HCP Healthcare Asia PTE Limited HCP Healthcare Asia PTE Limited
Share transfer (FY 2021)
76480.00000000 shares to Hari Kishore Sridharan
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Sunflower Chemicals Private Limited U24297TN2007PTC061964 Sivakasi, Tamil Nadu, India
N.S. Remedies Private Limited U24239WB2005PTC101586 Kolkata, West Bengal, India
Glx Chemicals Private Limited U51496DL2008PTC181038 Delhi, Delhi, India
Mulisha Chemical Works Pvt Ltd U24211MH1987PTC042323 Mumbai, Maharashtra, India
Runa Logistics Private Limited U74999MH2008PTC181755 Dombivali, Maharashtra, India
Lyfius Pharma Private Limited U24299AP2020PTC116443 Vishakhapatnam, Andhra Pradesh, India
Wictor Chemical Industries Private Limited U24110GJ2021PTC123586 Anjar, Gujarat, India
Gayatri Pharmaceuticals Pvt Ltd U24231OR1985PTC001551 Cuttack, Orissa, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Eucare Pharmaceuticals before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Eucare Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Eucare Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Eucare Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Eucare Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Eucare Pharmaceuticals an active company?

Eucare Pharmaceuticals has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Eucare Pharmaceuticals financially healthy?

Eucare Pharmaceuticals has a Financial Health Score of 25/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Eucare Pharmaceuticals?

Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Eucare Pharmaceuticals?

The ultimate holding entity is Hcp Healthcare Asia Pte. Ltd.. 5 active director(s) are on record.

Does Eucare Pharmaceuticals have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Eucare Pharmaceuticals up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Eucare Pharmaceuticals?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.